ACRV1 Inhibitors
ACRV1 inhibitors belong to a specific chemical class that exhibits the ability to modulate the activity of the ACRV1 protein. ACRV1, which stands for Acetyl-CoA carboxylase-related protein 1, is an enzyme that plays a vital role in various metabolic pathways within the human body. The inhibitors designed for ACRV1 specifically target the catalytic site or other relevant regions of the protein, aiming to hinder or regulate its function. By interacting with ACRV1, these inhibitors are thought to interfere with the enzymatic reactions and processes associated with the protein's normal activity. This modulation can result in downstream effects on metabolic pathways and cellular functions where ACRV1 is involved. The exact mechanisms of action for ACRV1 inhibitors may vary depending on the specific compound and its interaction with the protein.
Researchers and scientists have been exploring the properties and potential applications of ACRV1 inhibitors to gain a deeper understanding of their impact on cellular metabolism and other relevant biological processes. Through experimental studies and structural analyses, they aim to elucidate the precise binding interactions between the inhibitors and ACRV1, which can provide valuable insights into the underlying mechanisms of their inhibitory effects. The development and characterization of ACRV1 inhibitors contribute to expanding the knowledge and understanding of the complex interplay between metabolic pathways and cellular homeostasis. These inhibitors serve as valuable tools in basic research, allowing scientists to investigate the roles of ACRV1 in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
A small molecule inhibitor that selectively targets ACVR1 and has shown potential for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by abnormal bone formation. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
Another small molecule inhibitor that has demonstrated efficacy in research studies against ACVR1. It has been investigated for its potential use in FOP and other diseases involving abnormal bone formation. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
A potent and selective ACVR1 inhibitor that has shown therapeutic potential in inhibiting ACVR1-mediated BMP signaling, particularly in the context of fibrodysplasia ossificans progressiva. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
While primarily known as a c-Raf inhibitor, GW5074 has also been found to inhibit ACVR1, among other kinases. It has been used in research to explore the role of ACVR1 in various cellular processes. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
An ACVR1 inhibitor that selectively inhibits the BMP signaling pathway by targeting the kinase domain of ACVRIt has been studied for its potential in cancer therapy, as abnormal BMP signaling is associated with certain malignancies. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Although originally developed as an ALK5 inhibitor, SB431542 also inhibits ACVRIt has been widely used in research to explore TGF-β signaling and its involvement in various diseases. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
A small molecule inhibitor with selectivity for ACVR1, LDN-214117 has demonstrated efficacy in research studies for inhibiting ACVR1-mediated signaling. Its potential therapeutic applications are still being explored. | ||||||
ITD 1 | 1099644-42-4 | sc-507349 | 10 mg | $220.00 | ||
An ACVR1 inhibitor that selectively targets the kinase activity of ACVR1 and inhibits downstream signaling. It has been studied for its potential in blocking bone morphogenetic protein (BMP) signaling and modulating cellular processes. | ||||||